APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide Cancer Vaccine

Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.

Selected research

Market Analysis & Forecast

Global Peptide Cancer Vaccine Market Analysis and Forecast 2026-2032

2 January 2026190 pages

Choose your research edition.

Industry ResearchPeptide Cancer Vaccine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide Cancer Vaccine Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Peptide Cancer Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide Cancer Vaccine Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide Cancer Vaccine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.

Peptide Cancer Vaccine can be used for Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer and Others cancers. The most proportion research of Peptide Cancer Vaccine is about Melanoma, and the proportion is about 40%.

USA is the largest consumption place, with a consumption market share nearly 53% . Following USA, Europe is the second largest consumption place with the consumption market share of 31%.

Read the full market overview

Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech, Generex Biotechnology, ISA Pharmaceuticals and OncoTherapy Science are the key manufacturters of Peptide Cancer Vaccine.

This report presents an overview of global market for Peptide Cancer Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Peptide Cancer Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Peptide Cancer Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Peptide Cancer Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Peptide Cancer Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Peptide Cancer Vaccine sales, projected growth trends, production technology, application and end-user industry.

Peptide Cancer Vaccine Segment by Company

Boston Biomedical

Ultimovacs

BrightPath Biotherapeutics

TapImmune

Immatics

Sellas

Imugene

VAXON Biotech

Generex Biotechnology

ISA Pharmaceuticals

OncoTherapy Science

Peptide Cancer Vaccine Segment by Pipeline

ITK-1

GRN-1201

TPIV200

TPIV110

UV1

Galinpepimut-S

TARP 27-35

HER-Vaxx

Vx-001

Others

Peptide Cancer Vaccine Segment by Application

Breast Cancer

Lung Cancer

Melanoma

Prostate Cancer

Others

Peptide Cancer Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Cancer Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide Cancer Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Cancer Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Peptide Cancer Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Peptide Cancer Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide Cancer Vaccine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Peptide Cancer Vaccine Market Size Growth Rate by Pipeline (US$ Million), 2021 VS 2025 VS 2032 Table 2. ITK-1 Major Manufacturers Table 3. GRN-1201 Major Manufacturers Table 4. TPIV200 Major Manufacturers Table 5. TPIV110 Major Manufacturers Table 6. UV1 Major Manufacturers Table 7. Galinpepimut-S Major Manufacturers Table 8. TARP 27-35 Major Manufacturers Table 9. HER-Vaxx Major Manufacturers Table 10. Vx-001 Major Manufacturers Table 11. Others Major Manufacturers Table 12. Global Peptide Cancer Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 13. Breast Cancer Major Manufacturers Table 14. Lung Cancer Major Manufacturers Table 15. Melanoma Major Manufacturers Table 16. Prostate Cancer Major Manufacturers Table 17. Others Major Manufacturers Table 18. Peptide Cancer Vaccine Industry Trends Table 19. Peptide Cancer Vaccine Industry Drivers Table 20. Peptide Cancer Vaccine Industry Opportunities and Challenges Table 21. Peptide Cancer Vaccine Industry Restraints Table 22. Global Peptide Cancer Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 23. Global Peptide Cancer Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 24. Global Peptide Cancer Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 25. Global Peptide Cancer Vaccine Revenue Market Share by Region (2021-2026) Table 26. Global Peptide Cancer Vaccine Revenue Market Share by Region (2027-2032) Table 27. Global Peptide Cancer Vaccine Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Doses) Table 28. Global Peptide Cancer Vaccine Sales by Region (2021-2026) & (K Doses) Table 29. Global Peptide Cancer Vaccine Sales by Region (2027-2032) & (K Doses) Table 30. Global Peptide Cancer Vaccine Sales Market Share by Region (2021-2026) Table 31. Global Peptide Cancer Vaccine Sales Market Share by Region (2027-2032) Table 32. Global Peptide Cancer Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 33. Global Peptide Cancer Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 34. Global Peptide Cancer Vaccine Sales by Manufacturers (US$ Million) & (2021-2026) Table 35. Global Peptide Cancer Vaccine Sales Market Share by Manufacturers (2021-2026) Table 36. Global Peptide Cancer Vaccine Sales Price (USD/Dose) of Manufacturers (2021-2026) Table 37. Global Peptide Cancer Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 38. Global Peptide Cancer Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 39. Global Peptide Cancer Vaccine Manufacturers, Product Type & Application Table 40. Global Peptide Cancer Vaccine Manufacturers' Establishment Date Table 41. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 42. Global Peptide Cancer Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global Peptide Cancer Vaccine Revenue by Pipeline 2021 VS 2025 VS 2032 (US$ Million) Table 44. Global Peptide Cancer Vaccine Revenue by Pipeline (2021-2026) & (US$ Million) Table 45. Global Peptide Cancer Vaccine Revenue by Pipeline (2027-2032) & (US$ Million) Table 46. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2021-2026) Table 47. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2027-2032) Table 48. Global Peptide Cancer Vaccine Sales by Pipeline 2021 VS 2025 VS 2032 (K Doses) Table 49. Global Peptide Cancer Vaccine Sales by Pipeline (2021-2026) & (K Doses) Table 50. Global Peptide Cancer Vaccine Sales by Pipeline (2027-2032) & (K Doses) Table 51. Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2021-2026) Table 52. Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2027-2032) Table 53. Global Peptide Cancer Vaccine Price by Pipeline (2021-2026) & (USD/Dose) Table 54. Global Peptide Cancer Vaccine Price by Pipeline (2027-2032) & (USD/Dose) Table 55. Global Peptide Cancer Vaccine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Peptide Cancer Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 57. Global Peptide Cancer Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 58. Global Peptide Cancer Vaccine Revenue Market Share by Application (2021-2026) Table 59. Global Peptide Cancer Vaccine Revenue Market Share by Application (2027-2032) Table 60. Global Peptide Cancer Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Doses) Table 61. Global Peptide Cancer Vaccine Sales by Application (2021-2026) & (K Doses) Table 62. Global Peptide Cancer Vaccine Sales by Application (2027-2032) & (K Doses) Table 63. Global Peptide Cancer Vaccine Sales Market Share by Application (2021-2026) Table 64. Global Peptide Cancer Vaccine Sales Market Share by Application (2027-2032) Table 65. Global Peptide Cancer Vaccine Price by Application (2021-2026) & (USD/Dose) Table 66. Global Peptide Cancer Vaccine Price by Application (2027-2032) & (USD/Dose) Table 67. Boston Biomedical Company Information Table 68. Boston Biomedical Business Overview Table 69. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 70. Boston Biomedical Peptide Cancer Vaccine Product Portfolio Table 71. Boston Biomedical Recent Development Table 72. Ultimovacs Company Information Table 73. Ultimovacs Business Overview Table 74. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 75. Ultimovacs Peptide Cancer Vaccine Product Portfolio Table 76. Ultimovacs Recent Development Table 77. BrightPath Biotherapeutics Company Information Table 78. BrightPath Biotherapeutics Business Overview Table 79. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 80. BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio Table 81. BrightPath Biotherapeutics Recent Development Table 82. TapImmune Company Information Table 83. TapImmune Business Overview Table 84. TapImmune Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 85. TapImmune Peptide Cancer Vaccine Product Portfolio Table 86. TapImmune Recent Development Table 87. Immatics Company Information Table 88. Immatics Business Overview Table 89. Immatics Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 90. Immatics Peptide Cancer Vaccine Product Portfolio Table 91. Immatics Recent Development Table 92. Sellas Company Information Table 93. Sellas Business Overview Table 94. Sellas Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 95. Sellas Peptide Cancer Vaccine Product Portfolio Table 96. Sellas Recent Development Table 97. Imugene Company Information Table 98. Imugene Business Overview Table 99. Imugene Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 100. Imugene Peptide Cancer Vaccine Product Portfolio Table 101. Imugene Recent Development Table 102. VAXON Biotech Company Information Table 103. VAXON Biotech Business Overview Table 104. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 105. VAXON Biotech Peptide Cancer Vaccine Product Portfolio Table 106. VAXON Biotech Recent Development Table 107. Generex Biotechnology Company Information Table 108. Generex Biotechnology Business Overview Table 109. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 110. Generex Biotechnology Peptide Cancer Vaccine Product Portfolio Table 111. Generex Biotechnology Recent Development Table 112. ISA Pharmaceuticals Company Information Table 113. ISA Pharmaceuticals Business Overview Table 114. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 115. ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio Table 116. ISA Pharmaceuticals Recent Development Table 117. OncoTherapy Science Company Information Table 118. OncoTherapy Science Business Overview Table 119. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2021-2026) Table 120. OncoTherapy Science Peptide Cancer Vaccine Product Portfolio Table 121. OncoTherapy Science Recent Development Table 122. North America Peptide Cancer Vaccine Revenue by Pipeline (2021-2026) & (US$ Million) Table 123. North America Peptide Cancer Vaccine Revenue by Pipeline (2027-2032) & (US$ Million) Table 124. North America Peptide Cancer Vaccine Sales by Pipeline (2021-2026) & (K Doses) Table 125. North America Peptide Cancer Vaccine Sales by Pipeline (2027-2032) & (K Doses) Table 126. North America Peptide Cancer Vaccine Sales Price by Pipeline (2021-2026) & (USD/Dose) Table 127. North America Peptide Cancer Vaccine Sales Price by Pipeline (2027-2032) & (USD/Dose) Table 128. North America Peptide Cancer Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 129. North America Peptide Cancer Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 130. North America Peptide Cancer Vaccine Sales by Application (2021-2026) & (K Doses) Table 131. North America Peptide Cancer Vaccine Sales by Application (2027-2032) & (K Doses) Table 132. North America Peptide Cancer Vaccine Sales Price by Application (2021-2026) & (USD/Dose) Table 133. North America Peptide Cancer Vaccine Sales Price by Application (2027-2032) & (USD/Dose) Table 134. North America Peptide Cancer Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 135. North America Peptide Cancer Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 136. North America Peptide Cancer Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 137. North America Peptide Cancer Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Doses) Table 138. North America Peptide Cancer Vaccine Sales by Country (2021-2026) & (K Doses) Table 139. North America Peptide Cancer Vaccine Sales by Country (2027-2032) & (K Doses) Table 140. North America Peptide Cancer Vaccine Sales Price by Country (2021-2026) & (USD/Dose) Table 141. North America Peptide Cancer Vaccine Sales Price by Country (2027-2032) & (USD/Dose) Table 142. United States Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 143. Canada Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 144. Mexico Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 145. Europe Peptide Cancer Vaccine Revenue by Pipeline (2021-2026) & (US$ Million) Table 146. Europe Peptide Cancer Vaccine Revenue by Pipeline (2027-2032) & (US$ Million) Table 147. Europe Peptide Cancer Vaccine Sales by Pipeline (2021-2026) & (K Doses) Table 148. Europe Peptide Cancer Vaccine Sales by Pipeline (2027-2032) & (K Doses) Table 149. Europe Peptide Cancer Vaccine Sales Price by Pipeline (2021-2026) & (USD/Dose) Table 150. Europe Peptide Cancer Vaccine Sales Price by Pipeline (2027-2032) & (USD/Dose) Table 151. Europe Peptide Cancer Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 152. Europe Peptide Cancer Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 153. Europe Peptide Cancer Vaccine Sales by Application (2021-2026) & (K Doses) Table 154. Europe Peptide Cancer Vaccine Sales by Application (2027-2032) & (K Doses) Table 155. Europe Peptide Cancer Vaccine Sales Price by Application (2021-2026) & (USD/Dose) Table 156. Europe Peptide Cancer Vaccine Sales Price by Application (2027-2032) & (USD/Dose) Table 157. Europe Peptide Cancer Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 158. Europe Peptide Cancer Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 159. Europe Peptide Cancer Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 160. Europe Peptide Cancer Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Doses) Table 161. Europe Peptide Cancer Vaccine Sales by Country (2021-2026) & (K Doses) Table 162. Europe Peptide Cancer Vaccine Sales by Country (2027-2032) & (K Doses) Table 163. Europe Peptide Cancer Vaccine Sales Price by Country (2021-2026) & (USD/Dose) Table 164. Europe Peptide Cancer Vaccine Sales Price by Country (2027-2032) & (USD/Dose) Table 165. Germany Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 166. France Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 167. U.K. Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 168. Italy Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 169. Russia Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 170. Spain Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 171. Netherlands Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 172. Switzerland Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 173. Sweden Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 174. Poland Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 175. China Peptide Cancer Vaccine Revenue by Pipeline (2021-2026) & (US$ Million) Table 176. China Peptide Cancer Vaccine Revenue by Pipeline (2027-2032) & (US$ Million) Table 177. China Peptide Cancer Vaccine Sales by Pipeline (2021-2026) & (K Doses) Table 178. China Peptide Cancer Vaccine Sales by Pipeline (2027-2032) & (K Doses) Table 179. China Peptide Cancer Vaccine Sales Price by Pipeline (2021-2026) & (USD/Dose) Table 180. China Peptide Cancer Vaccine Sales Price by Pipeline (2027-2032) & (USD/Dose) Table 181. China Peptide Cancer Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 182. China Peptide Cancer Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 183. China Peptide Cancer Vaccine Sales by Application (2021-2026) & (K Doses) Table 184. China Peptide Cancer Vaccine Sales by Application (2027-2032) & (K Doses) Table 185. China Peptide Cancer Vaccine Sales Price by Application (2021-2026) & (USD/Dose) Table 186. China Peptide Cancer Vaccine Sales Price by Application (2027-2032) & (USD/Dose) Table 187. Asia Peptide Cancer Vaccine Revenue by Pipeline (2021-2026) & (US$ Million) Table 188. Asia Peptide Cancer Vaccine Revenue by Pipeline (2027-2032) & (US$ Million) Table 189. Asia Peptide Cancer Vaccine Sales by Pipeline (2021-2026) & (K Doses) Table 190. Asia Peptide Cancer Vaccine Sales by Pipeline (2027-2032) & (K Doses) Table 191. Asia Peptide Cancer Vaccine Sales Price by Pipeline (2021-2026) & (USD/Dose) Table 192. Asia Peptide Cancer Vaccine Sales Price by Pipeline (2027-2032) & (USD/Dose) Table 193. Asia Peptide Cancer Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 194. Asia Peptide Cancer Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 195. Asia Peptide Cancer Vaccine Sales by Application (2021-2026) & (K Doses) Table 196. Asia Peptide Cancer Vaccine Sales by Application (2027-2032) & (K Doses) Table 197. Asia Peptide Cancer Vaccine Sales Price by Application (2021-2026) & (USD/Dose) Table 198. Asia Peptide Cancer Vaccine Sales Price by Application (2027-2032) & (USD/Dose) Table 199. Asia Peptide Cancer Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 200. Asia Peptide Cancer Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 201. Asia Peptide Cancer Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 202. Asia Peptide Cancer Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Doses) Table 203. Asia Peptide Cancer Vaccine Sales by Country (2021-2026) & (K Doses) Table 204. Asia Peptide Cancer Vaccine Sales by Country (2027-2032) & (K Doses) Table 205. Asia Peptide Cancer Vaccine Sales Price by Country (2021-2026) & (USD/Dose) Table 206. Asia Peptide Cancer Vaccine Sales Price by Country (2027-2032) & (USD/Dose) Table 207. Japan Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 208. South Korea Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 209. India Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 210. Australia Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 211. Taiwan Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 212. Southeast Asia Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 213. SAMEA Peptide Cancer Vaccine Revenue by Pipeline (2021-2026) & (US$ Million) Table 214. SAMEA Peptide Cancer Vaccine Revenue by Pipeline (2027-2032) & (US$ Million) Table 215. SAMEA Peptide Cancer Vaccine Sales by Pipeline (2021-2026) & (K Doses) Table 216. SAMEA Peptide Cancer Vaccine Sales by Pipeline (2027-2032) & (K Doses) Table 217. SAMEA Peptide Cancer Vaccine Sales Price by Pipeline (2021-2026) & (USD/Dose) Table 218. SAMEA Peptide Cancer Vaccine Sales Price by Pipeline (2027-2032) & (USD/Dose) Table 219. SAMEA Peptide Cancer Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 220. SAMEA Peptide Cancer Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 221. SAMEA Peptide Cancer Vaccine Sales by Application (2021-2026) & (K Doses) Table 222. SAMEA Peptide Cancer Vaccine Sales by Application (2027-2032) & (K Doses) Table 223. SAMEA Peptide Cancer Vaccine Sales Price by Application (2021-2026) & (USD/Dose) Table 224. SAMEA Peptide Cancer Vaccine Sales Price by Application (2027-2032) & (USD/Dose) Table 225. SAMEA Peptide Cancer Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 226. SAMEA Peptide Cancer Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 227. SAMEA Peptide Cancer Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 228. SAMEA Peptide Cancer Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Doses) Table 229. SAMEA Peptide Cancer Vaccine Sales by Country (2021-2026) & (K Doses) Table 230. SAMEA Peptide Cancer Vaccine Sales by Country (2027-2032) & (K Doses) Table 231. SAMEA Peptide Cancer Vaccine Sales Price by Country (2021-2026) & (USD/Dose) Table 232. SAMEA Peptide Cancer Vaccine Sales Price by Country (2027-2032) & (USD/Dose) Table 233. Brazil Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 234. Argentina Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 235. Chile Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 236. Colombia Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 237. Peru Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 238. Saudi Arabia Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 239. Israel Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 240. UAE Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 241. Turkey Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 242. Iran Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 243. Egypt Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Table 244. Key Raw Materials Table 245. Raw Materials Key Suppliers Table 246. Peptide Cancer Vaccine Distributors List Table 247. Peptide Cancer Vaccine Customers List Table 248. Research Programs/Design for This Report Table 249. Authors List of This Report Table 250. Secondary Sources Table 251. Primary Sources List of Figures Figure 1. Peptide Cancer Vaccine Image Figure 2. Global Peptide Cancer Vaccine Market Size Growth Rate by Pipeline (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide Cancer Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. ITK-1 Image Figure 5. GRN-1201 Image Figure 6. TPIV200 Image Figure 7. TPIV110 Image Figure 8. UV1 Image Figure 9. Galinpepimut-S Image Figure 10. TARP 27-35 Image Figure 11. HER-Vaxx Image Figure 12. Vx-001 Image Figure 13. Others Image Figure 14. Global Peptide Cancer Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Peptide Cancer Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 16. Breast Cancer Image Figure 17. Lung Cancer Image Figure 18. Melanoma Image Figure 19. Prostate Cancer Image Figure 20. Others Image Figure 21. Global Peptide Cancer Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 22. Global Peptide Cancer Vaccine Revenue (2021-2032) & (US$ Million) Figure 23. Global Peptide Cancer Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Peptide Cancer Vaccine Revenue Market Share by Region: 2025 Versus 2032 Figure 25. Global Peptide Cancer Vaccine Revenue Market Share by Region (2021-2032) Figure 26. Global Peptide Cancer Vaccine Sales (2021-2032) & (K Doses) Figure 27. Global Peptide Cancer Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Doses) Figure 28. Global Peptide Cancer Vaccine Sales Market Share by Region (2021-2032) Figure 29. US & Canada & Mexico Peptide Cancer Vaccine Sales YoY (2021-2032) & (K Doses) Figure 30. Europe Peptide Cancer Vaccine Sales YoY (2021-2032) & (K Doses) Figure 31. China Peptide Cancer Vaccine Sales YoY (2021-2032) & (K Doses) Figure 32. Asia (Excluding China) Peptide Cancer Vaccine Sales YoY (2021-2032) & (K Doses) Figure 33. South America, Middle East and Africa Peptide Cancer Vaccine Sales YoY (2021-2032) & (K Doses) Figure 34. Global Peptide Cancer Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 35. Global Peptide Cancer Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 36. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 37. Global Peptide Cancer Vaccine Revenue by Pipeline (2021 VS 2025 VS 2032) & (US$ Million) Figure 38. Global Peptide Cancer Vaccine Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 39. Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2021-2032) Figure 40. Global Peptide Cancer Vaccine Sales by Pipeline (2021 VS 2025 VS 2032) & (K Doses) Figure 41. Global Peptide Cancer Vaccine Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 42. Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2021-2032) Figure 43. Global Peptide Cancer Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 44. Global Peptide Cancer Vaccine Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 45. Global Peptide Cancer Vaccine Revenue Market Share by Application (2021-2032) Figure 46. Global Peptide Cancer Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Doses) Figure 47. Global Peptide Cancer Vaccine Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 48. Global Peptide Cancer Vaccine Sales Market Share by Application (2021-2032) Figure 49. North America Peptide Cancer Vaccine Revenue Share by Pipeline (2021-2032) Figure 50. North America Peptide Cancer Vaccine Sales Share by Pipeline (2021-2032) Figure 51. North America Peptide Cancer Vaccine Revenue Share by Application (2021-2032) Figure 52. North America Peptide Cancer Vaccine Sales Share by Application (2021-2032) Figure 53. North America Peptide Cancer Vaccine Revenue Share by Country (2021-2032) Figure 54. North America Peptide Cancer Vaccine Sales Share by Country (2021-2032) Figure 55. Europe Peptide Cancer Vaccine Revenue Share by Pipeline (2021-2032) Figure 56. Europe Peptide Cancer Vaccine Sales Share by Pipeline (2021-2032) Figure 57. Europe Peptide Cancer Vaccine Revenue Share by Application (2021-2032) Figure 58. Europe Peptide Cancer Vaccine Sales Share by Application (2021-2032) Figure 59. Europe Peptide Cancer Vaccine Revenue Share by Country (2021-2032) Figure 60. Europe Peptide Cancer Vaccine Sales Share by Country (2021-2032) Figure 61. China Peptide Cancer Vaccine Revenue Share by Pipeline (2021-2032) Figure 62. China Peptide Cancer Vaccine Sales Share by Pipeline (2021-2032) Figure 63. China Peptide Cancer Vaccine Revenue Share by Application (2021-2032) Figure 64. China Peptide Cancer Vaccine Sales Share by Application (2021-2032) Figure 65. Asia Peptide Cancer Vaccine Revenue Share by Pipeline (2021-2032) Figure 66. Asia Peptide Cancer Vaccine Sales Share by Pipeline (2021-2032) Figure 67. Asia Peptide Cancer Vaccine Revenue Share by Application (2021-2032) Figure 68. Asia Peptide Cancer Vaccine Sales Share by Application (2021-2032) Figure 69. Asia Peptide Cancer Vaccine Revenue Share by Country (2021-2032) Figure 70. Asia Peptide Cancer Vaccine Sales Share by Country (2021-2032) Figure 71. SAMEA Peptide Cancer Vaccine Revenue Share by Pipeline (2021-2032) Figure 72. SAMEA Peptide Cancer Vaccine Sales Share by Pipeline (2021-2032) Figure 73. SAMEA Peptide Cancer Vaccine Revenue Share by Application (2021-2032) Figure 74. SAMEA Peptide Cancer Vaccine Sales Share by Application (2021-2032) Figure 75. SAMEA Peptide Cancer Vaccine Revenue Share by Country (2021-2032) Figure 76. SAMEA Peptide Cancer Vaccine Sales Share by Country (2021-2032) Figure 77. Peptide Cancer Vaccine Value Chain Figure 78. Manufacturing Cost Structure Figure 79. Peptide Cancer Vaccine Production Mode & Process Figure 80. Direct Comparison with Distribution Share Figure 81. Distributors Profiles Figure 82. Years Considered Figure 83. Research Process Figure 84. Key Executives Interviewed

Scope & coverage.

Types
  • ITK-1
  • GRN-1201
  • TPIV200
  • TPIV110
  • UV1
  • Galinpepimut-S
  • TARP 27-35
  • HER-Vaxx
  • Vx-001
  • Others
Applications
  • Breast Cancer
  • Lung Cancer
  • Melanoma
  • Prostate Cancer
  • Others
Companies covered
  • Boston Biomedical
  • Ultimovacs
  • BrightPath Biotherapeutics
  • TapImmune
  • Immatics
  • Sellas
  • Imugene
  • VAXON Biotech
  • Generex Biotechnology
  • ISA Pharmaceuticals
  • OncoTherapy Science

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Peptide Cancer Vaccine Market by Pipeline
  3. 1.2.1 Global Peptide Cancer Vaccine Market Size by Pipeline, 2021 VS 2025 VS 2032
  4. 1.2.2 ITK-1
  5. 1.2.3 GRN-1201
  6. 1.2.4 TPIV200
  7. 1.2.5 TPIV110
  8. 1.2.6 UV1
  9. 1.2.7 Galinpepimut-S
  10. 1.2.8 TARP 27-35
  11. 1.2.9 HER-Vaxx
  12. 1.2.10 Vx-001
  13. 1.2.11 Others
  14. 1.3 Peptide Cancer Vaccine Market by Application
  15. 1.3.1 Global Peptide Cancer Vaccine Market Size by Application, 2021 VS 2025 VS 2032
  16. 1.3.2 Breast Cancer
  17. 1.3.3 Lung Cancer
  18. 1.3.4 Melanoma
  19. 1.3.5 Prostate Cancer
  20. 1.3.6 Others
  21. 1.4 Assumptions and Limitations
  22. 1.5 Study Goals and Objectives
2 Peptide Cancer Vaccine Market Dynamics
  1. 2.1 Peptide Cancer Vaccine Industry Trends
  2. 2.2 Peptide Cancer Vaccine Industry Drivers
  3. 2.3 Peptide Cancer Vaccine Industry Opportunities and Challenges
  4. 2.4 Peptide Cancer Vaccine Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Peptide Cancer Vaccine Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Peptide Cancer Vaccine Revenue by Region
  3. 3.2.1 Global Peptide Cancer Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Peptide Cancer Vaccine Revenue by Region (2021-2026)
  5. 3.2.3 Global Peptide Cancer Vaccine Revenue by Region (2027-2032)
  6. 3.2.4 Global Peptide Cancer Vaccine Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Peptide Cancer Vaccine Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Peptide Cancer Vaccine Sales by Region
  9. 3.4.1 Global Peptide Cancer Vaccine Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Peptide Cancer Vaccine Sales by Region (2021-2026)
  11. 3.4.3 Global Peptide Cancer Vaccine Sales by Region (2027-2032)
  12. 3.4.4 Global Peptide Cancer Vaccine Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Peptide Cancer Vaccine Revenue by Manufacturers
  2. 4.1.1 Global Peptide Cancer Vaccine Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Peptide Cancer Vaccine Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Peptide Cancer Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Peptide Cancer Vaccine Sales by Manufacturers
  6. 4.2.1 Global Peptide Cancer Vaccine Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Peptide Cancer Vaccine Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Peptide Cancer Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Peptide Cancer Vaccine Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Peptide Cancer Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Peptide Cancer Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Peptide Cancer Vaccine Manufacturers, Product Type & Application
  13. 4.7 Global Peptide Cancer Vaccine Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Peptide Cancer Vaccine Market CR5 and HHI
  16. 4.8.2 2025 Peptide Cancer Vaccine Tier 1, Tier 2, and Tier 3
5 Peptide Cancer Vaccine Market by Type
  1. 5.1 Global Peptide Cancer Vaccine Revenue by Type
  2. 5.1.1 Global Peptide Cancer Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Peptide Cancer Vaccine Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Peptide Cancer Vaccine Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Peptide Cancer Vaccine Sales by Type
  6. 5.2.1 Global Peptide Cancer Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Peptide Cancer Vaccine Sales by Type (2021-2032) & (K Doses)
  8. 5.2.3 Global Peptide Cancer Vaccine Sales Market Share by Type (2021-2032)
  9. 5.3 Global Peptide Cancer Vaccine Price by Type
6 Peptide Cancer Vaccine Market by Application
  1. 6.1 Global Peptide Cancer Vaccine Revenue by Application
  2. 6.1.1 Global Peptide Cancer Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Peptide Cancer Vaccine Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Peptide Cancer Vaccine Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Peptide Cancer Vaccine Sales by Application
  6. 6.2.1 Global Peptide Cancer Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Peptide Cancer Vaccine Sales by Application (2021-2032) & (K Doses)
  8. 6.2.3 Global Peptide Cancer Vaccine Sales Market Share by Application (2021-2032)
  9. 6.3 Global Peptide Cancer Vaccine Price by Application
7 Company Profiles
  1. 7.1 Boston Biomedical
  2. 7.1.1 Boston Biomedical Company Information
  3. 7.1.2 Boston Biomedical Business Overview
  4. 7.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Boston Biomedical Peptide Cancer Vaccine Product Portfolio
  6. 7.1.5 Boston Biomedical Recent Developments
  7. 7.2 Ultimovacs
  8. 7.2.1 Ultimovacs Company Information
  9. 7.2.2 Ultimovacs Business Overview
  10. 7.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Ultimovacs Peptide Cancer Vaccine Product Portfolio
  12. 7.2.5 Ultimovacs Recent Developments
  13. 7.3 BrightPath Biotherapeutics
  14. 7.3.1 BrightPath Biotherapeutics Company Information
  15. 7.3.2 BrightPath Biotherapeutics Business Overview
  16. 7.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
  18. 7.3.5 BrightPath Biotherapeutics Recent Developments
  19. 7.4 TapImmune
  20. 7.4.1 TapImmune Company Information
  21. 7.4.2 TapImmune Business Overview
  22. 7.4.3 TapImmune Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 TapImmune Peptide Cancer Vaccine Product Portfolio
  24. 7.4.5 TapImmune Recent Developments
  25. 7.5 Immatics
  26. 7.5.1 Immatics Company Information
  27. 7.5.2 Immatics Business Overview
  28. 7.5.3 Immatics Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Immatics Peptide Cancer Vaccine Product Portfolio
  30. 7.5.5 Immatics Recent Developments
  31. 7.6 Sellas
  32. 7.6.1 Sellas Company Information
  33. 7.6.2 Sellas Business Overview
  34. 7.6.3 Sellas Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Sellas Peptide Cancer Vaccine Product Portfolio
  36. 7.6.5 Sellas Recent Developments
  37. 7.7 Imugene
  38. 7.7.1 Imugene Company Information
  39. 7.7.2 Imugene Business Overview
  40. 7.7.3 Imugene Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Imugene Peptide Cancer Vaccine Product Portfolio
  42. 7.7.5 Imugene Recent Developments
  43. 7.8 VAXON Biotech
  44. 7.8.1 VAXON Biotech Company Information
  45. 7.8.2 VAXON Biotech Business Overview
  46. 7.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 VAXON Biotech Peptide Cancer Vaccine Product Portfolio
  48. 7.8.5 VAXON Biotech Recent Developments
  49. 7.9 Generex Biotechnology
  50. 7.9.1 Generex Biotechnology Company Information
  51. 7.9.2 Generex Biotechnology Business Overview
  52. 7.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
  54. 7.9.5 Generex Biotechnology Recent Developments
  55. 7.10 ISA Pharmaceuticals
  56. 7.10.1 ISA Pharmaceuticals Company Information
  57. 7.10.2 ISA Pharmaceuticals Business Overview
  58. 7.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
  60. 7.10.5 ISA Pharmaceuticals Recent Developments
  61. 7.11 OncoTherapy Science
  62. 7.11.1 OncoTherapy Science Company Information
  63. 7.11.2 OncoTherapy Science Business Overview
  64. 7.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
  66. 7.11.5 OncoTherapy Science Recent Developments
8 North America
  1. 8.1 North America Peptide Cancer Vaccine Market Size by Pipeline
  2. 8.1.1 North America Peptide Cancer Vaccine Revenue by Pipeline (2021-2032)
  3. 8.1.2 North America Peptide Cancer Vaccine Sales by Pipeline (2021-2032)
  4. 8.1.3 North America Peptide Cancer Vaccine Price by Pipeline (2021-2032)
  5. 8.2 North America Peptide Cancer Vaccine Market Size by Application
  6. 8.2.1 North America Peptide Cancer Vaccine Revenue by Application (2021-2032)
  7. 8.2.2 North America Peptide Cancer Vaccine Sales by Application (2021-2032)
  8. 8.2.3 North America Peptide Cancer Vaccine Price by Application (2021-2032)
  9. 8.3 North America Peptide Cancer Vaccine Market Size by Country
  10. 8.3.1 North America Peptide Cancer Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Peptide Cancer Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Peptide Cancer Vaccine Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Peptide Cancer Vaccine Market Size by Pipeline
  2. 9.1.1 Europe Peptide Cancer Vaccine Revenue by Pipeline (2021-2032)
  3. 9.1.2 Europe Peptide Cancer Vaccine Sales by Pipeline (2021-2032)
  4. 9.1.3 Europe Peptide Cancer Vaccine Price by Pipeline (2021-2032)
  5. 9.2 Europe Peptide Cancer Vaccine Market Size by Application
  6. 9.2.1 Europe Peptide Cancer Vaccine Revenue by Application (2021-2032)
  7. 9.2.2 Europe Peptide Cancer Vaccine Sales by Application (2021-2032)
  8. 9.2.3 Europe Peptide Cancer Vaccine Price by Application (2021-2032)
  9. 9.3 Europe Peptide Cancer Vaccine Market Size by Country
  10. 9.3.1 Europe Peptide Cancer Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Peptide Cancer Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Peptide Cancer Vaccine Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Peptide Cancer Vaccine Market Size by Pipeline
  2. 10.1.1 China Peptide Cancer Vaccine Revenue by Pipeline (2021-2032)
  3. 10.1.2 China Peptide Cancer Vaccine Sales by Pipeline (2021-2032)
  4. 10.1.3 China Peptide Cancer Vaccine Price by Pipeline (2021-2032)
  5. 10.2 China Peptide Cancer Vaccine Market Size by Application
  6. 10.2.1 China Peptide Cancer Vaccine Revenue by Application (2021-2032)
  7. 10.2.2 China Peptide Cancer Vaccine Sales by Application (2021-2032)
  8. 10.2.3 China Peptide Cancer Vaccine Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Peptide Cancer Vaccine Market Size by Pipeline
  2. 11.1.1 Asia Peptide Cancer Vaccine Revenue by Pipeline (2021-2032)
  3. 11.1.2 Asia Peptide Cancer Vaccine Sales by Pipeline (2021-2032)
  4. 11.1.3 Asia Peptide Cancer Vaccine Price by Pipeline (2021-2032)
  5. 11.2 Asia Peptide Cancer Vaccine Market Size by Application
  6. 11.2.1 Asia Peptide Cancer Vaccine Revenue by Application (2021-2032)
  7. 11.2.2 Asia Peptide Cancer Vaccine Sales by Application (2021-2032)
  8. 11.2.3 Asia Peptide Cancer Vaccine Price by Application (2021-2032)
  9. 11.3 Asia Peptide Cancer Vaccine Market Size by Country
  10. 11.3.1 Asia Peptide Cancer Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Peptide Cancer Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Peptide Cancer Vaccine Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Peptide Cancer Vaccine Market Size by Pipeline
  2. 12.1.1 SAMEA Peptide Cancer Vaccine Revenue by Pipeline (2021-2032)
  3. 12.1.2 SAMEA Peptide Cancer Vaccine Sales by Pipeline (2021-2032)
  4. 12.1.3 SAMEA Peptide Cancer Vaccine Price by Pipeline (2021-2032)
  5. 12.2 SAMEA Peptide Cancer Vaccine Market Size by Application
  6. 12.2.1 SAMEA Peptide Cancer Vaccine Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Peptide Cancer Vaccine Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Peptide Cancer Vaccine Price by Application (2021-2032)
  9. 12.3 SAMEA Peptide Cancer Vaccine Market Size by Country
  10. 12.3.1 SAMEA Peptide Cancer Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Peptide Cancer Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Peptide Cancer Vaccine Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Peptide Cancer Vaccine Value Chain Analysis
  2. 13.1.1 Peptide Cancer Vaccine Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Peptide Cancer Vaccine Production Mode & Process
  6. 13.2 Peptide Cancer Vaccine Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Peptide Cancer Vaccine Distributors
  9. 13.2.3 Peptide Cancer Vaccine Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst